Details of the Drug Combinations

General Information of This Drug (ID: DMPAWBN)

Drug Name
GSK525762   DMPAWBN
Synonyms GSK-525762
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

329 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Bortezomib + GSK525762 DCDCXUV Bortezomib Amelanotic melanoma (Cell Line: A2058) [3]
Bortezomib + GSK525762 DC4GDPH Bortezomib Breast carcinoma (Cell Line: KPL1) [4]
Bortezomib + GSK525762 DCOVNX2 Bortezomib Carcinoma (Cell Line: MDAMB436) [4]
Bortezomib + GSK525762 DC32K0A Bortezomib Colon carcinoma (Cell Line: RKO) [4]
Bortezomib + GSK525762 DCGO5LT Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [4]
Cyclophosphamide + GSK525762 DC8N6ML Cyclophosphamide Adenocarcinoma (Cell Line: CAOV3) [3]
Cyclophosphamide + GSK525762 DCW0HBZ Cyclophosphamide Adenocarcinoma (Cell Line: NCIH520) [3]
Cyclophosphamide + GSK525762 DCWFR0P Cyclophosphamide Adenocarcinoma (Cell Line: NCIH23) [3]
Cyclophosphamide + GSK525762 DCDLW1R Cyclophosphamide Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + GSK525762 DC52LO2 Cyclophosphamide Adenocarcinoma (Cell Line: DLD1) [3]
Cyclophosphamide + GSK525762 DCNST3U Cyclophosphamide Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + GSK525762 DC90KSO Cyclophosphamide Adenocarcinoma (Cell Line: SW-620) [3]
Cyclophosphamide + GSK525762 DCHIK3X Cyclophosphamide Amelanotic melanoma (Cell Line: A2058) [3]
Cyclophosphamide + GSK525762 DCP4AFR Cyclophosphamide Germ cell tumour (Cell Line: PA1) [3]
Cyclophosphamide + GSK525762 DCRZKG5 Cyclophosphamide Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + GSK525762 DCUG23R Cyclophosphamide Malignant melanoma (Cell Line: HT144) [3]
Cyclophosphamide + GSK525762 DC4PABF Cyclophosphamide Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + GSK525762 DCDEZAZ Cyclophosphamide Malignant melanoma (Cell Line: UACC62) [3]
Cyclophosphamide + GSK525762 DCR68SZ Cyclophosphamide Malignant melanoma (Cell Line: RPMI7951) [3]
Cyclophosphamide + GSK525762 DCIBAAN Cyclophosphamide Mesothelioma (Cell Line: MSTO) [3]
Cyclophosphamide + GSK525762 DCSTLWI Cyclophosphamide Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + GSK525762 DCHE0HO Cyclophosphamide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Cyclophosphamide + GSK525762 DCKQARG Cyclophosphamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + GSK525762 DCYCQU1 Cyclophosphamide Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + GSK525762 DCNW7PM Cyclophosphamide Breast carcinoma (Cell Line: OCUBM) [4]
Cyclophosphamide + GSK525762 DCISQRC Cyclophosphamide Carcinoma (Cell Line: EFM192B) [4]
Cyclophosphamide + GSK525762 DCFG1PG Cyclophosphamide Colon adenocarcinoma (Cell Line: LOVO) [4]
Cyclophosphamide + GSK525762 DCWE5TX Cyclophosphamide Colon carcinoma (Cell Line: RKO) [4]
Cyclophosphamide + GSK525762 DCV3H7K Cyclophosphamide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dasatinib + GSK525762 DC9PXAC Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Dasatinib + GSK525762 DC3VYP4 Dasatinib Adenocarcinoma (Cell Line: A427) [3]
Dasatinib + GSK525762 DC2KXXR Dasatinib Adenocarcinoma (Cell Line: NCIH520) [3]
Dasatinib + GSK525762 DCEV0T7 Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [3]
Dasatinib + GSK525762 DCYLNLW Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
Dasatinib + GSK525762 DCW0S9D Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Dasatinib + GSK525762 DC69VCG Dasatinib Mesothelioma (Cell Line: MSTO) [3]
Dasatinib + GSK525762 DC44IC1 Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Dasatinib + GSK525762 DCUAAV3 Dasatinib Prostate carcinoma (Cell Line: VCAP) [3]
Dasatinib + GSK525762 DCNV16U Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Dasatinib + GSK525762 DCOUQTD Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Dasatinib + GSK525762 DCROVZ0 Dasatinib Carcinoma (Cell Line: EFM192B) [4]
Dexamethasone + GSK525762 DCC7VSS Dexamethasone Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Dexamethasone + GSK525762 DC7KVUE Dexamethasone Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Dexamethasone + GSK525762 DC6MTFC Dexamethasone Breast carcinoma (Cell Line: KPL1) [4]
Dexamethasone + GSK525762 DCUB7T6 Dexamethasone Breast carcinoma (Cell Line: OCUBM) [4]
Dexamethasone + GSK525762 DC3BZWQ Dexamethasone Carcinoma (Cell Line: EFM192B) [4]
Dexamethasone + GSK525762 DC5BFVO Dexamethasone Carcinoma (Cell Line: MDAMB436) [4]
Dexamethasone + GSK525762 DCIYX12 Dexamethasone Colon carcinoma (Cell Line: RKO) [4]
Dexamethasone + GSK525762 DC10JH8 Dexamethasone Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dexamethasone + GSK525762 DC3QNW9 Dexamethasone Adenocarcinoma (Cell Line: OVCAR3) [5]
Dexamethasone + GSK525762 DCL3DNU Dexamethasone Adenocarcinoma (Cell Line: DLD1) [5]
Dexamethasone + GSK525762 DCQXYMX Dexamethasone Adenocarcinoma (Cell Line: HT29) [5]
Dexamethasone + GSK525762 DCYXSWN Dexamethasone Adenocarcinoma (Cell Line: SW-620) [5]
Dexamethasone + GSK525762 DCN7EE4 Dexamethasone Germ cell tumour (Cell Line: PA1) [5]
Dexamethasone + GSK525762 DCD33X0 Dexamethasone Malignant melanoma (Cell Line: A375) [5]
Dexamethasone + GSK525762 DCPEXF1 Dexamethasone Malignant melanoma (Cell Line: HT144) [5]
Dexamethasone + GSK525762 DCLBMHJ Dexamethasone Malignant melanoma (Cell Line: SKMEL30) [5]
Dexamethasone + GSK525762 DC51FMU Dexamethasone Malignant melanoma (Cell Line: UACC62) [5]
Dexamethasone + GSK525762 DCN876R Dexamethasone Non small cell carcinoma (Cell Line: SKMES1) [5]
Dexamethasone + GSK525762 DCLU22L Dexamethasone Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Dexamethasone + GSK525762 DCNLY9E Dexamethasone Prostate carcinoma (Cell Line: LNCAP) [5]
Dexamethasone + GSK525762 DCAQ015 Dexamethasone Prostate carcinoma (Cell Line: VCAP) [5]
Doxorubicin + GSK525762 DCYVVXM Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Doxorubicin + GSK525762 DCY35CU Doxorubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + GSK525762 DC3HVR5 Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + GSK525762 DCBYE5C Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + GSK525762 DCDRG5H Erlotinib Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + GSK525762 DCXCCYV Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + GSK525762 DCUMHWB Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + GSK525762 DC2HLXW Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Estramustine + GSK525762 DCC43WJ Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Estramustine + GSK525762 DCLRTPP Estramustine Breast carcinoma (Cell Line: KPL1) [4]
Estramustine + GSK525762 DCPVF55 Estramustine Breast carcinoma (Cell Line: OCUBM) [4]
Estramustine + GSK525762 DC2NL91 Estramustine Carcinoma (Cell Line: EFM192B) [4]
Estramustine + GSK525762 DCEADE5 Estramustine Carcinoma (Cell Line: MDAMB436) [4]
Estramustine + GSK525762 DCK6ESG Estramustine Colon carcinoma (Cell Line: RKO) [4]
Estramustine + GSK525762 DCCDUD3 Estramustine Rectal adenocarcinoma (Cell Line: SW837) [4]
Estramustine + GSK525762 DCA35HV Estramustine Adenocarcinoma (Cell Line: NCIH2122) [5]
Estramustine + GSK525762 DC9QO9X Estramustine Adenocarcinoma (Cell Line: NCIH23) [5]
Estramustine + GSK525762 DCLJ4OU Estramustine Adenocarcinoma (Cell Line: COLO320DM) [5]
Estramustine + GSK525762 DC8ZS1S Estramustine Adenocarcinoma (Cell Line: DLD1) [5]
Estramustine + GSK525762 DCWDSFA Estramustine Adenocarcinoma (Cell Line: HCT116) [5]
Estramustine + GSK525762 DC3V4H5 Estramustine Adenocarcinoma (Cell Line: SW-620) [5]
Estramustine + GSK525762 DC07ECV Estramustine Amelanotic melanoma (Cell Line: A2058) [5]
Estramustine + GSK525762 DCRF32H Estramustine Malignant melanoma (Cell Line: A375) [5]
Estramustine + GSK525762 DCGWT2C Estramustine Malignant melanoma (Cell Line: SKMEL30) [5]
Estramustine + GSK525762 DCFRJSK Estramustine Malignant melanoma (Cell Line: UACC62) [5]
Estramustine + GSK525762 DCFMMEG Estramustine Mesothelioma (Cell Line: MSTO) [5]
Estramustine + GSK525762 DCA2HVD Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Estramustine + GSK525762 DCB108F Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Estramustine + GSK525762 DC3908F Estramustine Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + GSK525762 DCKHRTU Etoposide Adenocarcinoma (Cell Line: NCIH1650) [3]
Etoposide + GSK525762 DC7SDN6 Etoposide Adenocarcinoma (Cell Line: NCIH520) [3]
Etoposide + GSK525762 DCHSM0H Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Etoposide + GSK525762 DCDPMRZ Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Etoposide + GSK525762 DCAL2QA Etoposide Carcinoma (Cell Line: MDAMB436) [4]
Fluorouracil + GSK525762 DCZUO0V Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Fluorouracil + GSK525762 DCM6Z4C Fluorouracil Breast carcinoma (Cell Line: KPL1) [4]
Fluorouracil + GSK525762 DCD36JN Fluorouracil Carcinoma (Cell Line: EFM192B) [4]
Fluorouracil + GSK525762 DCGFOWN Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [4]
Fluorouracil + GSK525762 DCP7MKO Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + GSK525762 DC9J3N0 Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [5]
Fluorouracil + GSK525762 DCS7DXH Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [5]
Fluorouracil + GSK525762 DC4SGAW Fluorouracil Adenocarcinoma (Cell Line: A427) [5]
Fluorouracil + GSK525762 DCGFS5W Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [5]
Fluorouracil + GSK525762 DC8CRK7 Fluorouracil Adenocarcinoma (Cell Line: SW-620) [5]
Fluorouracil + GSK525762 DC384GJ Fluorouracil Amelanotic melanoma (Cell Line: A2058) [5]
Fluorouracil + GSK525762 DCZJ4Q3 Fluorouracil Germ cell tumour (Cell Line: PA1) [5]
Fluorouracil + GSK525762 DCHTGXY Fluorouracil Malignant melanoma (Cell Line: HT144) [5]
Fluorouracil + GSK525762 DCRBQ6P Fluorouracil Mesothelioma (Cell Line: MSTO) [5]
Fluorouracil + GSK525762 DC245NF Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [5]
Fluorouracil + GSK525762 DCMWW3R Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Fluorouracil + GSK525762 DC6G3CR Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Fluorouracil + GSK525762 DCUB79E Fluorouracil Prostate carcinoma (Cell Line: VCAP) [5]
Fluorouracil + GSK525762 DC6I9M1 Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [5]
GSK525762 + Idarubicin DC658LJ Idarubicin Glioblastoma? (Cell Line: T98G) [3]
GSK525762 + Sorafenib DC5EGYN Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
GSK525762 + RTB101 DCUDUBJ RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
GSK525762 + RTB101 DC2MCV8 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
GSK525762 + RTB101 DCALCIV RTB101 Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + SCH-900776 DC827FI SCH-900776 Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + SCH-900776 DC5FMR9 SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [4]
GSK525762 + 10-hydroxycamptothecin DCTGQ2O 10-hydroxycamptothecin Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + SNX-2112 DC5C6BK SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
GSK525762 + SNX-2112 DCHVSGR SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
GSK525762 + SNX-2112 DC0KO9R SNX-2112 Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + SNX-2112 DCCY7DH SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
GSK525762 + SNX-2112 DCSQ1WS SNX-2112 Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + SNX-2112 DCVMBZL SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [4]
GSK525762 + SNX-2112 DCEPS8Q SNX-2112 Colon carcinoma (Cell Line: RKO) [4]
GSK525762 + SNX-2112 DCPRQFF SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
GSK525762 + Ridaforolimus DC94LVZ Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
GSK525762 + Ridaforolimus DCTE3SH Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
GSK525762 + Ridaforolimus DC15WQT Ridaforolimus Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + Ridaforolimus DCYWRG4 Ridaforolimus Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + MK-4827 DCW32E6 MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
GSK525762 + MK-4827 DCLO6BN MK-4827 Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + Lomustine DC2TT9H Lomustine Breast carcinoma (Cell Line: OCUBM) [4]
GSK525762 + Sorafenib DCE70HU Sorafenib Breast carcinoma (Cell Line: ZR751) [4]
GSK525762 + Sorafenib DC0EYQ6 Sorafenib Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + Sorafenib DCQ3VOM Sorafenib Breast carcinoma (Cell Line: OCUBM) [4]
GSK525762 + Sorafenib DCQCU28 Sorafenib Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + Sorafenib DC3ONF7 Sorafenib Colon adenocarcinoma (Cell Line: LOVO) [4]
GSK525762 + Sorafenib DCW9HK2 Sorafenib Colon carcinoma (Cell Line: RKO) [4]
GSK525762 + Sorafenib DCDN4TC Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [4]
GSK525762 + Sorafenib DCVGBIO Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [4]
GSK525762 + Vorinostat DCPEY3B Vorinostat Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + Ruxolitinib DCPMM2G Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [5]
GSK525762 + RTB101 DC73YR0 RTB101 Adenocarcinoma (Cell Line: A427) [5]
GSK525762 + RTB101 DCEUHW5 RTB101 Adenocarcinoma (Cell Line: NCIH1650) [5]
GSK525762 + RTB101 DCW0PMM RTB101 Adenocarcinoma (Cell Line: NCIH2122) [5]
GSK525762 + RTB101 DCNC2IQ RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
GSK525762 + SCH-900776 DC7FMHF SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [5]
GSK525762 + SCH-900776 DCGK8F8 SCH-900776 Adenocarcinoma (Cell Line: SW-620) [5]
GSK525762 + SCH-900776 DCZM1RY SCH-900776 Mesothelioma (Cell Line: MSTO) [5]
GSK525762 + SCH-900776 DCPYA84 SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
GSK525762 + 10-hydroxycamptothecin DCHK4D4 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [5]
GSK525762 + 10-hydroxycamptothecin DCRYY97 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [5]
GSK525762 + 10-hydroxycamptothecin DCXDNSX 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
GSK525762 + 10-hydroxycamptothecin DC1PPVT 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
GSK525762 + SNX-2112 DCGLFEH SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [5]
GSK525762 + SNX-2112 DC08Y9W SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [5]
GSK525762 + SNX-2112 DC9MBPA SNX-2112 Adenocarcinoma (Cell Line: A427) [5]
GSK525762 + SNX-2112 DCNY6I7 SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [5]
GSK525762 + SNX-2112 DCW35PO SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [5]
GSK525762 + SNX-2112 DCNJJQ7 SNX-2112 Adenocarcinoma (Cell Line: HCT116) [5]
GSK525762 + SNX-2112 DCUCACI SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [5]
GSK525762 + SNX-2112 DCKIXMV SNX-2112 Mesothelioma (Cell Line: MSTO) [5]
GSK525762 + SNX-2112 DCSB052 SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [5]
GSK525762 + SNX-2112 DCFW3OD SNX-2112 Prostate carcinoma (Cell Line: VCAP) [5]
GSK525762 + Ridaforolimus DC2BSLI Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [5]
GSK525762 + Ridaforolimus DCXO43Z Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [5]
GSK525762 + Ridaforolimus DC3OGA9 Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [5]
GSK525762 + Ridaforolimus DC4ER79 Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
GSK525762 + Ridaforolimus DCKZ18U Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [5]
GSK525762 + MK-4827 DCNL1QJ MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [5]
GSK525762 + MK-4827 DCOAV7N MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [5]
GSK525762 + MK-4827 DCEGI4M MK-4827 Mesothelioma (Cell Line: MSTO) [5]
GSK525762 + MK-4827 DCJJ0YW MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [5]
GSK525762 + Lomustine DC3GETX Lomustine Adenocarcinoma (Cell Line: HCT116) [5]
GSK525762 + Lomustine DCGJ5EZ Lomustine Mesothelioma (Cell Line: MSTO) [5]
GSK525762 + Lomustine DCA7CLG Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
GSK525762 + Sorafenib DCF59Q1 Sorafenib Adenocarcinoma (Cell Line: CAOV3) [5]
GSK525762 + Sorafenib DCSKCSD Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [5]
GSK525762 + Sorafenib DCDWYMH Sorafenib Adenocarcinoma (Cell Line: A427) [5]
GSK525762 + Sorafenib DCE71CB Sorafenib Adenocarcinoma (Cell Line: NCIH2122) [5]
GSK525762 + Sorafenib DCAXH7Z Sorafenib Adenocarcinoma (Cell Line: NCIH520) [5]
GSK525762 + Sorafenib DCPQYMC Sorafenib Adenocarcinoma (Cell Line: SW-620) [5]
GSK525762 + Sorafenib DCXV3UM Sorafenib Amelanotic melanoma (Cell Line: A2058) [5]
GSK525762 + Sorafenib DCROL0T Sorafenib Germ cell tumour (Cell Line: PA1) [5]
GSK525762 + Sorafenib DC7MWAL Sorafenib Malignant melanoma (Cell Line: A375) [5]
GSK525762 + Sorafenib DC3QCAO Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [5]
GSK525762 + Sorafenib DC1SWZP Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Idarubicin + GSK525762 DCSZ8T3 Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Idarubicin + GSK525762 DC7VQ3D Idarubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Idarubicin + GSK525762 DCCPGMW Idarubicin Breast carcinoma (Cell Line: ZR751) [4]
Idarubicin + GSK525762 DCIIOPZ Idarubicin Breast carcinoma (Cell Line: OCUBM) [4]
Idarubicin + GSK525762 DCCRAJG Idarubicin Carcinoma (Cell Line: OV90) [4]
Idarubicin + GSK525762 DCNW3UV Idarubicin Carcinoma (Cell Line: EFM192B) [4]
Idarubicin + GSK525762 DCUTV2S Idarubicin Carcinoma (Cell Line: MDAMB436) [4]
Idarubicin + GSK525762 DCS0JZU Idarubicin Colon adenocarcinoma (Cell Line: LOVO) [4]
Idarubicin + GSK525762 DCH43ZO Idarubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Idarubicin + GSK525762 DCUXRBQ Idarubicin Rectal adenocarcinoma (Cell Line: SW837) [4]
Idarubicin + GSK525762 DCYVYLR Idarubicin Adenocarcinoma (Cell Line: CAOV3) [5]
Idarubicin + GSK525762 DCYG5V5 Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [5]
Idarubicin + GSK525762 DCA5EWL Idarubicin Adenocarcinoma (Cell Line: A427) [5]
Idarubicin + GSK525762 DCOMSYM Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [5]
Idarubicin + GSK525762 DCQNS7Y Idarubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Idarubicin + GSK525762 DCH09WN Idarubicin Adenocarcinoma (Cell Line: NCIH520) [5]
Idarubicin + GSK525762 DCCZS5X Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Idarubicin + GSK525762 DCGINVR Idarubicin Adenocarcinoma (Cell Line: DLD1) [5]
Idarubicin + GSK525762 DCYK55D Idarubicin Adenocarcinoma (Cell Line: HCT116) [5]
Idarubicin + GSK525762 DCERMII Idarubicin Adenocarcinoma (Cell Line: HT29) [5]
Idarubicin + GSK525762 DCW8JLE Idarubicin Adenocarcinoma (Cell Line: SW-620) [5]
Idarubicin + GSK525762 DC9LAL3 Idarubicin Amelanotic melanoma (Cell Line: A2058) [5]
Idarubicin + GSK525762 DCNV777 Idarubicin Germ cell tumour (Cell Line: PA1) [5]
Idarubicin + GSK525762 DCGGFG6 Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Idarubicin + GSK525762 DCQR30U Idarubicin Malignant melanoma (Cell Line: A375) [5]
Idarubicin + GSK525762 DCWYY4R Idarubicin Malignant melanoma (Cell Line: HT144) [5]
Idarubicin + GSK525762 DCCO826 Idarubicin Malignant melanoma (Cell Line: RPMI7951) [5]
Idarubicin + GSK525762 DCNY6TU Idarubicin Malignant melanoma (Cell Line: SKMEL30) [5]
Idarubicin + GSK525762 DCTA3XW Idarubicin Malignant melanoma (Cell Line: UACC62) [5]
Idarubicin + GSK525762 DCI2G2Z Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Idarubicin + GSK525762 DCZG9XK Idarubicin Non small cell carcinoma (Cell Line: SKMES1) [5]
Idarubicin + GSK525762 DCMQI83 Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Idarubicin + GSK525762 DC7RZNG Idarubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Idarubicin + GSK525762 DCLLYNA Idarubicin Prostate carcinoma (Cell Line: LNCAP) [5]
Idarubicin + GSK525762 DCKATEH Idarubicin Prostate carcinoma (Cell Line: VCAP) [5]
Lapatinib + GSK525762 DCZYH53 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Lapatinib + GSK525762 DC711JG Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Lapatinib + GSK525762 DCLK50I Lapatinib Breast carcinoma (Cell Line: KPL1) [4]
Lapatinib + GSK525762 DCO7KE5 Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [5]
Lapatinib + GSK525762 DCNSVNL Lapatinib Germ cell tumour (Cell Line: PA1) [5]
Lapatinib + GSK525762 DCY0QUU Lapatinib Malignant melanoma (Cell Line: A375) [5]
Lapatinib + GSK525762 DCUE4Z7 Lapatinib Mesothelioma (Cell Line: MSTO) [5]
Lapatinib + GSK525762 DCI9Y9Z Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lapatinib + GSK525762 DCC5YCB Lapatinib Prostate carcinoma (Cell Line: LNCAP) [5]
Metformin + GSK525762 DCSDAEM Metformin Adenocarcinoma (Cell Line: CAOV3) [3]
Metformin + GSK525762 DC4T3HR Metformin Adenocarcinoma (Cell Line: NCIH23) [3]
Metformin + GSK525762 DCBQNDW Metformin Adenocarcinoma (Cell Line: COLO320DM) [3]
Metformin + GSK525762 DC19W0D Metformin Adenocarcinoma (Cell Line: DLD1) [3]
Metformin + GSK525762 DCEH086 Metformin Adenocarcinoma (Cell Line: HT29) [3]
Metformin + GSK525762 DC0QJTE Metformin Amelanotic melanoma (Cell Line: A2058) [3]
Metformin + GSK525762 DCT69VE Metformin Germ cell tumour (Cell Line: PA1) [3]
Metformin + GSK525762 DCLJ2R2 Metformin Malignant melanoma (Cell Line: RPMI7951) [3]
Metformin + GSK525762 DCKY3DH Metformin Malignant melanoma (Cell Line: SKMEL30) [3]
Metformin + GSK525762 DC7OTOE Metformin Malignant melanoma (Cell Line: UACC62) [3]
Metformin + GSK525762 DC7AINK Metformin Non small cell carcinoma (Cell Line: SKMES1) [3]
Metformin + GSK525762 DCVIDGB Metformin Prostate carcinoma (Cell Line: LNCAP) [3]
Metformin + GSK525762 DCJQN3R Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Metformin + GSK525762 DCIAPS8 Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Metformin + GSK525762 DCS1LBA Metformin Carcinoma (Cell Line: OV90) [4]
Metformin + GSK525762 DCPCAEQ Metformin Carcinoma (Cell Line: EFM192B) [4]
Metformin + GSK525762 DCA19FU Metformin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Methotrexate + GSK525762 DCP6UNG Methotrexate Adenocarcinoma (Cell Line: NCIH520) [3]
Methotrexate + GSK525762 DCSD8C3 Methotrexate Malignant melanoma (Cell Line: SKMEL30) [3]
Methotrexate + GSK525762 DCC4E4U Methotrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Methotrexate + GSK525762 DCVXMPX Methotrexate Rectal adenocarcinoma (Cell Line: SW837) [4]
Mitomycin + GSK525762 DCSPHOB Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Mitomycin + GSK525762 DCET7BG Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Mitomycin + GSK525762 DC7VVBH Mitomycin Breast carcinoma (Cell Line: KPL1) [4]
Mitomycin + GSK525762 DCM557O Mitomycin Adenocarcinoma (Cell Line: OVCAR3) [5]
Mitomycin + GSK525762 DCTT1ID Mitomycin Adenocarcinoma (Cell Line: NCIH1650) [5]
Mitomycin + GSK525762 DC5U31T Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-1775 + GSK525762 DCZ9JNY MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + GSK525762 DCK7PJ9 MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-1775 + GSK525762 DC4CW9F MK-1775 Colon carcinoma (Cell Line: RKO) [4]
MK-1775 + GSK525762 DC6K20C MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-2206 + GSK525762 DC7VY89 MK-2206 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-2206 + GSK525762 DC1JPYV MK-2206 Malignant melanoma (Cell Line: A375) [3]
MK-2206 + GSK525762 DCSHZ7C MK-2206 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-2206 + GSK525762 DCO9587 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-2206 + GSK525762 DCOW5C5 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-2206 + GSK525762 DCUT2AW MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-2206 + GSK525762 DCUP9PM MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
MK-2206 + GSK525762 DCCTZ8X MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-5108 + GSK525762 DC7G1UH MK-5108 Carcinoma (Cell Line: MDAMB436) [4]
MK-5108 + GSK525762 DCQVTVP MK-5108 Colon carcinoma (Cell Line: RKO) [4]
MK-5108 + GSK525762 DCV1ATR MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-5108 + GSK525762 DC1SWCL MK-5108 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-5108 + GSK525762 DCC5GD9 MK-5108 Adenocarcinoma (Cell Line: DLD1) [5]
MK-5108 + GSK525762 DCCTUH5 MK-5108 Malignant melanoma (Cell Line: A375) [5]
MK-5108 + GSK525762 DCLFO5V MK-5108 Malignant melanoma (Cell Line: HT144) [5]
MK-5108 + GSK525762 DCP097C MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-5108 + GSK525762 DCNP5R7 MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-5108 + GSK525762 DC9X6TN MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PD-0325901 + GSK525762 DCVYBRZ PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + GSK525762 DC5SDMT PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + GSK525762 DCC82Q6 PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + GSK525762 DCT6FEF PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [5]
PD-0325901 + GSK525762 DCRH5UX PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
PD-0325901 + GSK525762 DCVYA37 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PD-0325901 + GSK525762 DCGB5B1 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [5]
PMID28460551-Compound-2 + GSK525762 DCPK02H PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PMID28460551-Compound-2 + GSK525762 DCA2VQF PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PMID28460551-Compound-2 + GSK525762 DCGZW09 PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [4]
PMID28460551-Compound-2 + GSK525762 DCCA785 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [5]
PMID28460551-Compound-2 + GSK525762 DC1XD27 PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
PMID28460551-Compound-2 + GSK525762 DCCCYGD PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
SCH 727965 + GSK525762 DCCPGB4 SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
SCH 727965 + GSK525762 DC4ADUK SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
SCH 727965 + GSK525762 DC5JBBF SCH 727965 Breast carcinoma (Cell Line: OCUBM) [4]
SCH 727965 + GSK525762 DCQCSBE SCH 727965 Carcinoma (Cell Line: OV90) [4]
SCH 727965 + GSK525762 DCD3N8V SCH 727965 Carcinoma (Cell Line: MDAMB436) [4]
SCH 727965 + GSK525762 DCRQZ86 SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SCH 727965 + GSK525762 DC5DZDR SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [5]
SCH 727965 + GSK525762 DC23MYV SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
SCH 727965 + GSK525762 DCOO6US SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [5]
SCH 727965 + GSK525762 DCR9QWK SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Taxol + GSK525762 DCCEC9C Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Taxol + GSK525762 DC9T5VT Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Taxol + GSK525762 DC7I2LZ Taxol Breast carcinoma (Cell Line: OCUBM) [4]
Taxol + GSK525762 DCM6X3U Taxol Carcinoma (Cell Line: MDAMB436) [4]
Taxol + GSK525762 DCQVT9F Taxol Adenocarcinoma (Cell Line: COLO320DM) [5]
Topotecan + GSK525762 DCL9W04 Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Topotecan + GSK525762 DCOTE7T Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Topotecan + GSK525762 DC2DTSN Topotecan Invasive ductal carcinoma (Cell Line: T-47D) [4]
Topotecan + GSK525762 DCKFUQC Topotecan Adenocarcinoma (Cell Line: OVCAR3) [5]
Topotecan + GSK525762 DCSHDZ1 Topotecan Adenocarcinoma (Cell Line: A427) [5]
Topotecan + GSK525762 DC7X0ZU Topotecan Amelanotic melanoma (Cell Line: A2058) [5]
Topotecan + GSK525762 DCNAE5D Topotecan Prostate carcinoma (Cell Line: VCAP) [5]
Vinblastine + GSK525762 DCZSDDS Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinblastine + GSK525762 DC8LYL2 Vinblastine Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + GSK525762 DCQDQNN Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + GSK525762 DCL6FMR Vinorelbine Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + GSK525762 DCTATZU Vinorelbine Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + GSK525762 DCUHJ11 Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + GSK525762 DCKC13J Vinorelbine Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + GSK525762 DCQLWU8 Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 329 DrugCom(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7033).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.